Staley Capital Advisers Inc. Has $666,000 Holdings in Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Staley Capital Advisers Inc. grew its position in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 25.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,000 shares of the biotechnology company’s stock after buying an additional 10,000 shares during the quarter. Staley Capital Advisers Inc. owned approximately 0.87% of Atara Biotherapeutics worth $666,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC lifted its position in shares of Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after acquiring an additional 4,043 shares in the last quarter. State Street Corp raised its stake in Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares during the period. Vestal Point Capital LP lifted its holdings in shares of Atara Biotherapeutics by 11.3% in the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after purchasing an additional 12,677 shares in the last quarter. Finally, FMR LLC boosted its position in shares of Atara Biotherapeutics by 41.7% in the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after buying an additional 7,381 shares during the period. 70.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Rodman & Renshaw started coverage on Atara Biotherapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $25.00 price target on the stock. RODMAN&RENSHAW downgraded Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 21st. TD Cowen upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. HC Wainwright reaffirmed a “neutral” rating on shares of Atara Biotherapeutics in a research report on Tuesday, January 28th. Finally, Canaccord Genuity Group cut their target price on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, January 17th. One analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $17.75.

Atara Biotherapeutics Stock Performance

Shares of ATRA opened at $6.16 on Tuesday. The firm has a market cap of $35.48 million, a PE ratio of -0.24 and a beta of 0.49. The firm’s 50 day moving average price is $9.74 and its 200 day moving average price is $9.74. Atara Biotherapeutics, Inc. has a twelve month low of $5.40 and a twelve month high of $20.81.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings results on Friday, March 7th. The biotechnology company reported ($1.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.82) by $2.63. The business had revenue of $32.75 million for the quarter, compared to the consensus estimate of $20.58 million. On average, sell-side analysts anticipate that Atara Biotherapeutics, Inc. will post -10.39 earnings per share for the current fiscal year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.